Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 972 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Drug A (Blinded Drug) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY4268989 (MORF-057) in Healthy Participants

NCT06964776
View directory record Official record
Conditions
Healthy
Interventions
LY4268989, Placebo, Midazolam
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Not applicable Interventional Results available

Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza

NCT00555893
View directory record Official record
Conditions
Influenza
Interventions
Oseltamivir, Placebo
Drug
Lead sponsor
Marshfield Clinic Research Foundation
Other
Eligibility
1 Year to 79 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 15, 2026, 9:47 PM EDT
Withdrawn Phase 2 Interventional

Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty:

NCT02342977
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Avascular Necrosis
Interventions
Placebo, Lacosamide
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

NCT02500121
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Placebo, Pembrolizumab
Other · Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
28
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Clarity: A Study of Health and Wellness Products on Mental Clarity and Health Outcomes

NCT05652725
View directory record Official record
Conditions
Cognitive Function
Interventions
Clarity Active Study Product 1.1 Usage, Clarity Active Study Product 2.1 Usage, Clarity Active Study Product 3.1 Usage, Clarity Active Study Product 4.1 Usage, Clarity Active Study Product 4.2 Usage, Clarity Active Study Product 4.3 Usage, Placebo Control Form 1, Placebo Control Form 2, Placebo Control Form 3, Placebo Control Form 4, Placebo Control Form 5, Clarity Active Study Product 5.1 Usage, Clarity Active Study Product 5.2 Usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
4,826 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 3 Interventional

Abatacept for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's)

NCT02108860
View directory record Official record
Conditions
Granulomatosis With Polyangiitis (Wegener's), Granulomatosis With Polyangiitis, Wegener's Granulomatosis, ANCA-Associated Vasculitis
Interventions
Abatacept, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
15 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 15, 2026, 9:47 PM EDT
Recruiting Not applicable Interventional

Telehealth-Enhanced Asthma Care for Home After the Emergency Room

NCT05844891
View directory record Official record
Conditions
Asthma in Children
Interventions
Telehealth-Enhanced Asthma Care for Home After the Emergency Room (TEACH-ER), Enhanced Care (EC)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 12 Years
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety and Toxicity of Polyphenon E (EGCG) in HIV-1-Infected Individuals

NCT01433289
View directory record Official record
Conditions
HIV Infection
Interventions
Polyphenon E, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2023 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 4 Interventional Results available

Trial of Azithromycin vs. Doxycycline for the Treatment of Rectal Chlamydia in MSM

NCT03608774
View directory record Official record
Conditions
Anal Chlamydia Infection
Interventions
Azithromycin, Doxycycline, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years · Male only
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP)

NCT04630158
View directory record Official record
Conditions
Chronic Ocular Pain
Interventions
SAF312 Placebo, SAF312
Other · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
24
States / cities
Mission Hills, California • Newport Beach, California • Palo Alto, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis

NCT00050882
View directory record Official record
Conditions
Gastroparesis
Interventions
GM-611
Drug
Lead sponsor
Chugai Pharma USA
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
67
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 59 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

NCT00558844
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Arikayce™ 560 mg, Placebo for 560 mg, Arikayce™ 70 mg, Arikayce™ 140 mg, Placebo for 70 mg / 140 mg
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
6 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2019 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Safety Study in Humans of a Single Dose of CPG 52364

NCT00547014
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2009 · Synced Oct 15, 2026, 9:47 PM EDT
Recruiting Phase 3 Interventional

Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula

NCT06807437
View directory record Official record
Conditions
Pancreatic Carcinoma, Pancreatic Neoplasm
Interventions
Biospecimen Collection, Distal Pancreatectomy, Lanreotide, Questionnaire Administration, Saline
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
118
States / cities
Birmingham, Alabama • Daphne, Alabama • Fairhope, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 15, 2026, 9:47 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

BRIDGE Device for Treatment of Opioid Withdrawal

NCT04162145
View directory record Official record
Conditions
Opioid Withdrawal, Pain, Craving
Interventions
Active BRIDGE device placement, Inactive BRIDGE device placement
Device
Lead sponsor
BrightView LLC
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

NCT00825916
View directory record Official record
Conditions
Scar Prevention, Scar Reduction
Interventions
AZX100 Drug Product, Placebo
Drug
Lead sponsor
Capstone Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 15, 2026, 9:47 PM EDT
Active, not recruiting Phase 4 Interventional

Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation

NCT03119584
View directory record Official record
Conditions
Chronic Constipation, Diabete Mellitus
Interventions
linaclotide or placebo
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 3 Interventional Results available

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants

NCT03881696
View directory record Official record
Conditions
Peanut Allergy, Multi-food Allergy
Interventions
Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Year to 55 Years
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
10
States / cities
Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 15, 2026, 9:47 PM EDT
Terminated Phase 2 Interventional Results available

Double-Blind Placebo Controlled Study of Safety,Tolerability, and Efficacy of LiRIS® in Women With Interstitial Cystitis

NCT01475253
View directory record Official record
Conditions
Interstitial Cystitis
Interventions
Lidocaine Releasing Intravesical System - LiRIS®, LiRIS Placebo, Sham Cystoscopy Procedure
Drug · Other · Procedure
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older · Female only
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
27
States / cities
Glendale, Arizona • Glendora, California • Stanford, California + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2015 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Confirmatory Study of HFVI Guided Analgesic Administration in Surgical Subjects

NCT04049656
View directory record Official record
Conditions
Analgesia
Interventions
HFVI
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Oct 15, 2026, 9:47 PM EDT
Terminated Phase 4 Interventional Results available

Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU)

NCT01059929
View directory record Official record
Conditions
Mechanical Ventilation, Critical Illness
Interventions
Dexmedetomidine, Propofol, Fentanyl, Midazolam, Physical and Occupational Therapy
Drug · Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 15, 2026, 9:47 PM EDT
Terminated Phase 3 Interventional Results available

Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation

NCT02177266
View directory record Official record
Conditions
Atrial Fibrillation, Post-pericardiotomy Syndrome, Constriction
Interventions
Colchicine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Oct 15, 2026, 9:47 PM EDT
Terminated Phase 2 Interventional Results available

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

NCT00752206
View directory record Official record
Conditions
Osteosarcoma
Interventions
Saracatinib, Placebo
Drug
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Other
Eligibility
15 Years to 74 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 15, 2026, 9:47 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant

NCT01122784
View directory record Official record
Conditions
Plague Vaccine
Interventions
rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
Biological
Lead sponsor
DynPort Vaccine Company LLC, A GDIT Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
11
States / cities
San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 15, 2026, 9:47 PM EDT